Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Public ClinicalTrials.gov record NCT02553317. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis
Study identification
- NCT ID
- NCT02553317
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2015 (Actual)
- Primary completion
- Aug 2017 (Actual)
- Completion
- Aug 2017 (Actual)
- Last update posted
- Apr 5, 2023
2015 – 2017
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site | Birmingham | Alabama | 35249 | — |
| Investigator Site | Los Angeles | California | 90033 | — |
| Investigator Site | Atlanta | Georgia | 30322 | — |
| Investigator Site | Boston | Massachusetts | 02114 | — |
| Investigator Site | St Louis | Missouri | 63110 | — |
| Investigator Site | Rochester | New York | 14642 | — |
| Investigator Site | Rochester | New York | 55905 | — |
| Investigator Site | Valhalla | New York | 10595 | — |
| Investigator Site | Chapel Hill | North Carolina | 27599 | — |
| Investigator Site | Durham | North Carolina | 27710 | — |
| Investigator Site | Winston-Salem | North Carolina | 27157 | — |
| Investigator SIte | Cleveland | Ohio | 44195 | — |
| Investigator Site | Columbus | Ohio | 43210 | — |
| Investigator Site | Oklahoma City | Oklahoma | 73104 | — |
| Investigator Site | Pittsburgh | Pennsylvania | 15213 | — |
| Investigator Site | Charleston | South Carolina | 29425 | — |
| Investigator Site | Greenville | South Carolina | 27834 | — |
| Investigator Site | Houston | Texas | 77030 | — |
| Investigator Site | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02553317, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02553317 live on ClinicalTrials.gov.